RO.CH

267.8

+0.07%↑

NOVN.CH

95.11

+0.44%↑

RO.CH

267.8

+0.07%↑

NOVN.CH

95.11

+0.44%↑

RO.CH

267.8

+0.07%↑

NOVN.CH

95.11

+0.44%↑

RO.CH

267.8

+0.07%↑

NOVN.CH

95.11

+0.44%↑

RO.CH

267.8

+0.07%↑

NOVN.CH

95.11

+0.44%↑

Search

Lonza Group AG

Geschlossen

BrancheGesundheitswesen

556.8 -1.59

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

555.8

Max

568.2

Schlüsselkennzahlen

By Trading Economics

Einkommen

307M

Verkäufe

3.5B

KGV

Branchendurchschnitt

54.451

40.048

EPS

4.31

Dividendenrendite

0.71

Gewinnspanne

8.729

Angestellte

19,299

EBITDA

764M

Empfehlungen

By TipRanks

Empfehlungen

Starkes Kaufsignal

12-Monats-Prognose

+18.16% upside

Dividenden

By Dow Jones

Dividendenrendite

Branchendurchschnitt

0.71%

2.45%

Nächstes Ergebnis

23. Okt. 2025

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

-2.5B

40B

Vorheriger Eröffnungskurs

558.39

Vorheriger Schlusskurs

556.8

Lonza Group AG Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

23. Juli 2025, 08:30 UTC

Ergebnisse
Wichtige Markttreiber

Lonza Shares Rise After Outlook Lift for Core Business

9. Mai 2025, 05:18 UTC

Ergebnisse

Lonza Doesn't Expect Tariff Hit, Backs Outlook for CDMO Business

18. Feb. 2025, 12:22 UTC

Akquisitionen, Fusionen, Übernahmen

Lonza Picks BofA, Centerview Partners for Capsules Unit Sale, Bloomberg Law Says, Citing Sources

23. Juli 2025, 08:00 UTC

Market Talk
Ergebnisse

Lonza Nudges Up Full-Year Guidance for Core Business After Good Results -- Market Talk

23. Juli 2025, 04:44 UTC

Ergebnisse

Lonza 1H Sales Grew 19% at Constant Currency

23. Juli 2025, 04:43 UTC

Ergebnisse

Lonza 1H Core Ebitda Margin 29.6%

23. Juli 2025, 04:43 UTC

Ergebnisse

Lonza: Margins Will Be Only Minimally Affected

23. Juli 2025, 04:42 UTC

Ergebnisse

Lonza Expects FX Headwind of -2.5% to -3.5% on 2025 Sales and Core Ebitda

23. Juli 2025, 04:42 UTC

Ergebnisse

Lonza: This Is Mainly From Weakening of U.S. Dollar

23. Juli 2025, 04:38 UTC

Ergebnisse

Lonza 1H Net Pft CHF426M

23. Juli 2025, 04:37 UTC

Ergebnisse

Lonza Backs 2025 View for CHI Business

23. Juli 2025, 04:36 UTC

Ergebnisse

Lonza Had Seen CDMO Business Core Ebitda Margin Approaching 30% in 2025

23. Juli 2025, 04:36 UTC

Ergebnisse

Lonza Sees CDMO Business Core Ebitda Margin of 30%-31% in 2025

23. Juli 2025, 04:35 UTC

Ergebnisse

Lonza Had Expected 2025 CDMO Business Sales Growth at Constant Currency of About 20%

23. Juli 2025, 04:35 UTC

Ergebnisse

Lonza Expects 2025 CDMO Business Sales Growth at Constant Currency of 20%-21%

23. Juli 2025, 04:33 UTC

Ergebnisse

Lonza Upgrades 2025 Full-Year CDMO Sales and Margin Outlook

23. Juli 2025, 04:32 UTC

Ergebnisse

Lonza 1H EBITDA CHF1.01B

23. Juli 2025, 04:32 UTC

Ergebnisse

Lonza 1H Core Ebitda CHF1.06B

23. Juli 2025, 04:32 UTC

Ergebnisse

Analysts Saw Lonza 1H Sales at CHF3.51B

23. Juli 2025, 04:32 UTC

Ergebnisse

Analysts Saw Lonza 1H Core Ebitda at CHF1.00B

23. Juli 2025, 04:31 UTC

Ergebnisse

Lonza 1H Sales CHF3.58B

23. Juli 2025, 04:31 UTC

Ergebnisse

Lonza Backs 2025 View

25. Juni 2025, 05:27 UTC

Market Talk
Akquisitionen, Fusionen, Übernahmen

Lonza Group Looks Well-placed to Benefit From U.S. Pharma Trade Policy -- Market Talk

28. Mai 2025, 05:38 UTC

Market Talk

Lonza Looks Like Tariff Winner -- Market Talk

9. Mai 2025, 14:45 UTC

Market Talk

Big Pharma's U.S. Expansion Will Take Years to Materialize, Lonza CFO Says -- Market Talk

9. Mai 2025, 14:42 UTC

Market Talk

Big Pharma U.S. Investment Plans Might Not Bring Extra Spending, Lonza CFO Says -- Market Talk

8. Apr. 2025, 07:34 UTC

Market Talk

Lonza Well Protected From Tariffs -- Market Talk

29. Jan. 2025, 08:11 UTC

Market Talk
Ergebnisse

Lonza's Outlook Looks Positive -- Market Talk

29. Jan. 2025, 07:22 UTC

Market Talk
Ergebnisse

Lonza Had a Mixed Year Across Divisions -- Market Talk

29. Jan. 2025, 07:11 UTC

Market Talk
Ergebnisse

Lonza's Results Don't Contain Any Surprises -- Market Talk

Peer-Vergleich

Kursveränderung

Lonza Group AG Prognose

Kursziel

By TipRanks

18.16% Vorteil

12-Monats-Prognose

Durchschnitt 675.89 CHF  18.16%

Hoch 753 CHF

Tief 630 CHF

Basierend auf 9 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Lonza Group AG – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

9 ratings

8

Buy

1

Halten

0

Sell

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Lonza Group AG

Lonza Group AG, together with its subsidiaries, supplies various products and services for pharmaceutical, biotech, and nutrition markets in Europe, North and Central America, Latin America, Asia, Australia, New Zealand, and internationally. It operates through Biologics, Small Molecules, Cell & Gene, and Capsules & Health Ingredients segments. The Biologics segment engages in the contract development and manufacturing of biopharmaceuticals for clinical and commercial manufacturing needs throughout the product lifecycle, including drug substance and drug product manufacturing. The Small Molecules segment operates as an integrated development and manufacturing service provider for small molecule drug substances and their intermediates. This segment also supports customers across various aspects of design, development, and manufacturing, including particle engineering and drug product packaging. The Cell & Gene segment develops technologies and platforms that industrialize the manufacturing processes and production of cell and gene therapies; offers contract development and manufacturing services, and regulatory support for a range of allogeneic and autologous cell therapies, and exosome-based therapies, as well as viral vector gene therapies. This segment also provides Cocoon platform, a closed automated system for patient-scale cell therapy manufacturing; and specialty raw materials and enabling technology solutions in cell and gene therapy, injectable drugs, vaccines, and bio-manufacturing markets. The Capsules & Health Ingredients segment offers capsules, dosage form solutions, and health ingredients for pharmaceutical and nutraceutical customers. Lonza Group AG was incorporated in 1897 and is headquartered in Basel, Switzerland.